BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20332676)

  • 21. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 22. Developing better treatments in hepatocellular carcinoma.
    Duffy A; Greten T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
    Carr BI; Carroll S; Muszbek N; Gondek K
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of sorafenib in patients with hepatocellular or renal carcinoma].
    Rosmorduc O; Chevreau C; Dielenseger P; Ederhy S; Goldwasser F; Grange JD; Mortier L; Neidhardt-Berard ME; Robert C; Scotté F; Seitz JF
    Gastroenterol Clin Biol; 2010 Mar; 34(3):161-7. PubMed ID: 20181452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 27. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
    Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
    Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
    Welker MW; Lubomierski N; Gog C; Herrmann E; Engels K; Vogl TJ; Bechstein WO; Zeuzem S; Trojan J
    J Chemother; 2010 Jun; 22(3):205-11. PubMed ID: 20566428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract]   [Full Text] [Related]  

  • 30. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
    Zhu AX
    Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK
    Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib in advanced hepatocellular carcinoma.
    Copur MS
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatocellular carcinoma: the search for innovative adjuvant therapies.
    Yen Y; Zhou W
    Oncology (Williston Park); 2009 Dec; 23(14):1291, 1294. PubMed ID: 20120843
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sorafenib in the treatment of hepatocellular carcinoma].
    Suchánková G; Spicák J
    Vnitr Lek; 2011 May; 57(5):485-90. PubMed ID: 21695929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.